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Effects of Topical and Subconjunctival Bevacizumab in
High-Risk Corneal Transplant Survival
Mohammad H. Dastjerdi,1,2,3,4 Daniel R. Saban,1,2,4 Andre Okanobo,1,2,3
Nambi Nallasamy,1,2 Zahra Sadrai,1,2 Sunil K. Chauhan,1,2 Amir R. Hajrasouliha,1,2 and
Reza Dana1,2,3
PURPOSE. To investigate whether corneal graft survival could be
improved by topical or subconjunctival bevacizumab in a mu-
rine model of vascularized high-risk corneal transplantation.
METHODS. Before corneal transplantation, intrastromal sutures
were placed for 2 weeks in the corneas of BALB/c mice,
inducing intense angiogenesis. Allogeneic corneal transplanta-
tion was performed using C57BL/6 donor mice. Topical bev-
acizumab (2.5%) was delivered 3 times a day for 3 weeks in one
treatment group, and 0.02 mL (0.5 mg) bevacizumab was
injected subconjunctivally at days 0, 4, 8, and 15 after trans-
plantation in the other treatment group. The control group
received no treatment. Grafts were examined twice a week for
8 weeks by slit-lamp microscopy and were photographed once
a week by slit-lamp digital camera and scored for opacity. For
assessment of corneal neovascularization (NV), a quantitative
method was used to measure three primary metrics including
neovascular area, vessel caliber, and neovessel invasion area.
RESULTS. Both topical and subconjunctival bevacizumab treat-
ment reduced neovascular area and vessel caliber; however,
the regression of corneal NV was more profound when treated
subconjunctivally. The mean percentage reduction of neovas-
cular area was 55% (P  0.05) by week 8 in the subconjunc-
tival treatment group and 33% (P  0.15) in the topical group.
Only subconjunctival bevacizumab treatment resulted in signif-
icant regression of neovessel invasion area (P  0.05). All
corneal transplants in both the control and the topical groups
were rejected by 4 weeks after transplantation. However, in
the subconjunctival treatment group, 33% of corneal grafts
survived (P  0.01).
CONCLUSIONS. Subconjunctival bevacizumab may offer an ad-
junctive measure to conventional therapies in preventing graft
rejection in high-risk corneal transplantation. (Invest Ophthal-
mol Vis Sci. 2010;51:2411–2417) DOI:10.1167/iovs.09-3745
Allograft rejection is a leading cause of corneal graft failureand thus a leading indication for repeat penetrating kera-
toplasty.1 Indeed, repeat grafting as a result of previous failure
has become the second leading indication for corneal trans-
plantation, as reported.2 It has been known for many decades
that the presence of preexisting blood vessels is a strong risk
factor for corneal graft immune rejection.3–5 Grafting into
vascularized corneal beds, or so-called high-risk corneal trans-
plantations, leads to a rate of immune rejection of greater than
50%, even with a strict regimen of topical and systemic immu-
nosuppressive drugs.6 In fact, stratification of risk factors for
immunologic rejection in penetrating keratoplasty has identi-
fied recipient vascularization as a critical proximal cause for
earlier and more fulminant rejection episodes.4,5,7,8
Targeting angiogenesis to modulate immune responses after
corneal transplantation has been the core area of interest for
many investigators.9–13 Why the relative immunologic quies-
cence of the eye, which is a central facet of its immunoprivi-
leged state, is disturbed in patients with corneal neovascular-
ization (NV) is not fully understood.14 However, experimental
evidence strongly suggests that molecular factors such as the
local immunosuppressive cytokine milieu (transforming
growth factor-, -melanocyte-stimulating hormone) and func-
tional attributes (anterior chamber-associated immune devia-
tion), which play a critical role in maintaining the physiologic
quiescence in the anterior segment, are subverted in the pres-
ence of corneal NV.14 In addition to blood vessels in vascular-
ized high-risk corneas, lymphatic neovessels can ingrow in
parallel with hemangiogenesis, facilitating effective access of
donor and host antigen-presenting cells and antigenic material
to regional lymph nodes, where accelerated sensitization to
graft antigens occurs.15,16 Thus, treatment of corneal NV after
corneal transplantation can potentially limit both the afferent
(sensitization) and efferent (rejection) arms of alloimmunity
and, hence, reduce the propensity for immunoinflammatory
reactions that can jeopardize graft survival.14
Vascular endothelial growth factor (VEGF) is thought to be
a key mechanistic mediator of NV.17 The prominent role of
VEGF in the pathophysiology of corneal NV has been demon-
strated in experimental models of corneal angiogenesis.18 It
has been shown that VEGF is upregulated in inflamed and
vascularized corneas in humans and in animal models.19 VEGF
inhibitors, including pegaptanib sodium, ranibizumab, and be-
vacizumab, are used for the treatment of neovascular age-
related macular degeneration.20 Recently, there has been grow-
ing interest in using topical and subconjunctival anti-VEGF for
the treatment of corneal NV.21–26 Our data in a prospective
clinical study have demonstrated a significant reduction in the
severity of corneal NV in response to topical bevacizumab
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therapy in patients with stable corneal NV.27 In an animal
model of high-risk corneal transplantation, it has also been
shown that intraperitoneal (systemic) injection of a VEGF-
neutralizing cytokine trap can improve corneal graft survival.12
These reports suggest that treatment with topical or locally
injected anti-VEGF could offer an adjunctive measure to con-
ventional therapies (e.g., corticosteroids) to curb the inciting
factors of graft rejection in the setting of vascularized high-risk
corneal transplantation. Therefore, we sought to evaluate
whether corneal graft survival in vascularized high-risk corneal
transplantation can be improved by initiating local (topical or
subconjunctival) bevacizumab treatment in a murine model.
To make a thorough and comprehensive assessment of corneal
NV, a quantitative method was implemented to measure three
primary metrics—neovascular area, vessel caliber, and neoves-
sel invasion area. Our results indicate that while both topical
and subconjunctival bevacizumab therapy inhibit corneal NV
after high-risk transplantation, only the subconjunctival route
is significantly effective in improving graft survival.
METHODS
Animals and Anesthesia
Eight- to 12-week-old C57BL/6 and BALB/c male mice were obtained
from Taconic Farms (Germantown, NY). Mice were housed in a spe-
cific pathogen-free environment at the Schepens Eye Research Institute
animal facility. All animals were treated according to guidelines estab-
lished by the ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research and the Public Health Policy on Humane Care and
Use of Laboratory Animals (US Public Health Review), and all proce-
dures were approved by the Institutional Animal Care and Use Com-
mittee. Anesthesia was administered intraperitoneally by ketamine/
xylazine solution at a dose of 120 mg/kg body weight and 20 mg/kg
body weight, respectively.
High-Risk Graft Bed Preparation
Aspects of this procedure were adapted and modified from Cursiefen
et al.28 to enhance corneal NV. First a 1.5-mm trephine was used to
mark the central corneas of BALB/c mice. A figure-of-eight suture knot
was then placed with two intrastromal incursions approximately 120°
apart, and each incursion extended apically from slightly above the
limbus to the trephine demarcation (Fig. 1A). Three interrupted figure-
of-eight suture knots were placed using 11-0 nylon sutures (Sharpoint;
Vanguard, Houston, TX) for 14 days, after which graft beds exhibited
extensive neovascularization. At this time, the sutures were removed,
and penetrating corneal transplantation was performed using age-
matched C57BL/6 donors.
Corneal Transplantation
This procedure has been detailed elsewhere.29 Briefly, the central
cornea (2-mm diameter) was excised from a donor mouse using scis-
sors (Vannas; Storz Instruments, San Dimas, CA) and was placed on ice
in corneal preservation media (Optisol-GS; Bausch and Lomb, Roches-
ter, NY). The graft bed was prepared by excising a 1.5-mm site in the
central cornea of a recipient mouse. A donor button was then placed
onto the recipient bed and was secured with eight interrupted 11-0
nylon sutures (Sharpoint, Reading, PA) (Fig. 1B). Graft survival was
evaluated regularly twice a week using a slit-lamp biomicroscope over
the course of 8 weeks. We used a standardized opacity-grading (range,
0–5) scheme to identify rejection,29 defined as a score of 3 for
two consecutive examinations.
Bevacizumab Treatment
Topical bevacizumab 2.5% (25 mg/mL; Avastin; Genentech, South San
Francisco, CA) was applied three times a day for 3 weeks in one
treatment group (n  10). For the subconjunctival group (n  10), a
volume of 0.02 mL bevacizumab 2.5% (0.5 mg) was injected at days 0,
4, 8, and 15 after transplantation. The control group (n  10) received
no treatment.
Quantification of Corneal Neovascularization
We developed a method to objectively quantify corneal NV for
application of this study. This method consists of first capturing a
series of digital slit-lamp images of corneas and then, using graphics
editing software (Photoshop CS2; Adobe Systems Inc., Mountain
View, CA) to digitally trace the blood vessels in a corneal image to
1. 2. 3.
A.
B.
Border  of paracentral
cornea (marked with
1.5 mm trephine)
Figure-of-eight suture
Limbus
FIGURE 1. Preparation of robust high-
risk graft beds for orthotopic corneal
transplantation. (A) Schematic depic-
tion of the figure-eight knot used cre-
ated with two intrastromal incur-
sions, each extending from slightly
above the limbus to the circumfer-
ence of the paracentral cornea,
which was marked with a 1.5-mm
trephine. Three of these suture knots
were placed in BALB/c mice to stim-
ulate robust corneal neovasculariza-
tion (B1). After 14 days the sutures
were removed (B2), and penetrating
corneal transplantation was per-
formed using age-matched C57BL/6
donors (B3).
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remove the background of nonvessel areas (Fig. 2A). This method
yields a very clear picture with which to qualitatively evaluate
corneal NV levels in vivo (Fig. 3A) and, importantly, allows each
individual mouse to be followed at various time points throughout
the study (Fig. 3B). In this regard, this method is different from
other quantitative image analyses that have been designed for im-
munohistologic assessment of corneal lymphangiogenesis and he-
mangiogenesis.30,31 Three primary metrics for corneal NV were
considered (Fig. 2B). The first, referred to as the neovascular area
(NA), involves measuring the area of the corneal vessels themselves
when projected onto the plane of a photograph. The second metric,
referred to as vessel caliber (VC), involves determining an approx-
imate mean diameter of the corneal vessels. The third metric,
referred to as invasion area (IA), measures the fraction of corneal
area in which vessels are present. We analyzed all the corneal
images quantitatively using a mathematical software program (Mat-
Lab; MathWorks Inc., Natick, MA) written specifically to calculate
these corneal NV parameters. After the blood vessels were en-
hanced and traced by using different graphics editing (Photoshop
CS2; Adobe Systems Inc.) tools and filters, by setting a threshold
level, the nonvessel area was erased, and the remaining neovascular
area was pixelized and measured. The calculated blood vessel area
was normalized to the whole corneal area to obtain the NA score for
each corneal picture. VC was also estimated by using a computa-
tional technique to measure the largest diameter circle centered at
each pixel inside a blood vessel. The mean value across all pixels
within blood vessels was taken as an estimate of the mean VC for a
given image. Last, the IA was quantified, and the ends of all vascular
sprouts were marked. By connecting all these marks, the contour of
the IA was traced and the measured area was again normalized to
the whole corneal area (Fig. 2B).
Statistical Analysis
Error bars displayed in the figures were calculated from the SEM.
Statistical analyses, including Student’s t-tests, were performed
throughout the study, as indicated in the respective figure captions.
Kaplan-Meier analysis constructed survival curves and respective log
rank tests compared with rates of corneal graft survival. P  0.05 was
considered significant.
RESULTS
Comparison of Topical versus Subconjunctival
Bevacizumab Treatment on Corneal NV
We first compared the effects of topical versus subconjunctival
bevacizumab treatment in suppressing corneal NV after high-
risk corneal transplantation. We found that though both topical
and subconjunctival delivery of bevacizumab inhibited corneal
NV after high-risk transplantation, subconjunctival treatment
was clearly more effective to this end (Fig. 3B). This was the
case for early time points (e.g., week 1) and late time points
(e.g., weeks 4 and 8) after transplantation (Fig. 3B).
Neovascular Area
At baseline, there was no statistically significant difference in
the mean NA among the three study groups. Although NA
Vessel Caliber (VC) Invasion Area (IA)
Neovascular Area (NA)
A.
B.
FIGURE 2. Quantification of corneal
neovascularization. Digital slit-lamp
corneal pictures were analyzed using
graphics editing software and a math-
ematical program. After the total cor-
neal area was outlined, the blood ves-
sels were enhanced and traced by
using different graphics editing tools
and filters. By setting a threshold
level, the nonvessel area was erased,
and the remaining neovascular area
was then pixelized and measured.
Three metrics were computed using
a mathematical script: NA, which
measures the area of the corneal ves-
sels themselves; VC, which deter-
mines an approximate mean diame-
ter of the corneal vessels; and IA,
which measures the fraction of cor-
neal area in which vessels are
present.
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values in all three groups decreased, by the week 4 time point
it became clear that the subconjunctival route of bevacizumab
was considerably more effective than the topical route in
reducing NA (Fig. 4A) because the subconjunctival values were
significantly and markedly lower than control at weeks 4 (P 
0.05), 6 (P  0.05), and 8 (P  0.05). The mean percentage
reduction of NA in the topical group was 15% at week 2, 39%
at week 4, 13% at week 6, and 33% at week 8, whereas these
values in the subconjunctival group were 33% at week 2, 51%
at week 4, 50% at week 6, and 55% at week 8. In the control
group, the mean percentage reductions of NA were 27%, 26%,
19%, and 13% in weeks 2, 4, 6, and 8, respectively.
Vessel Caliber
Estimation of VC using a computational technique showed that
values for the three groups were not statistically different at
baseline. These values dropped in all three groups to the same
level by week 2 and remained relatively stable until week 6.
However, control values then rose substantially by week 8, but
subconjunctival treatment group remained statistically lower
than in the control group (P  0.03). Topical bevacizumab
treatment group showed a very marginal statistical significant
difference from the control group in reduction of VC at week
8 (P  0.05) (Fig. 4B).
Subconj. TreatmentControl Topical Treatment
W
eek 1
W
eek 4
W
eek 8
A.
B.
FIGURE 3. Comparison of topical and
subconjunctival bevacizumab on cor-
neal neovascularization in high-risk
corneal transplantation. (A) High ac-
curacy of digital tracing of blood ves-
sels to evaluate corneal neovascular-
ization. Representative slit-lamp images
of high-risk corneal transplantation
and their respective traces of corneal
neovessel patterns demonstrate the
accuracy of this technique. (B) En-
hanced efficacy of subconjunctival
bevacizumab treatment for inhibiting
corneal neovascularization in high-
risk transplantation. Representative
images of corneal neovessel patterns
are presented at the various times
after transplantation of mice treated
either topically (n  10) or subcon-
junctivally (n  10) with bevaci-
zumab or left untreated as controls
(n  10).
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Invasion Area
As for the other two metrics, no statistically significant differ-
ence in neovessel IA was shown any at baseline between the
different study groups. Control and topical groups showed
increases rather than significant declines in their IA values (Fig.
4C). The mean percentage reduction values for IA were 8%,
1%, 8%, and 6% in the control group and 2%, 1%, 1%,
and 8% in the topical group by weeks 2, 4, 6, and 8, respec-
tively. Interestingly, subconjunctival treatment appeared to be
the only effective method for reduce IA (Fig. 4C) because those
values remained significantly lower than in the control group at
weeks 4 (P  0.01), 6 (P  0.01), and 8 (P  0.025). Mean
percentage reductions for IA in the subconjunctival group
were 2%, 10%, 9%, and 8% at weeks 2, 4, 6, and 8, respectively.
Increased Efficacy of Subconjunctival versus
Topical Bevacizumab on High-Risk Corneal
Allograft Survival
To test whether treatment with topical or subconjunctival
bevacizumab could promote allograft survival in the high-risk
setting, the opacity of transplanted corneal grafts was exam-
ined and scored regularly to 8 weeks after transplantation by
slit-lamp examination. We found that mice treated topically
with bevacizumab did not exhibit a reduced mean opacity
score (Fig. 5) or a statistical difference from the mean score of
the untreated controls (P  0.05). In contrast, mice treated
subconjunctivally with bevacizumab exhibited a reduced mean
opacity score (Fig. 5) that was significantly lower than that of
the untreated controls at weeks 2 (P 0.01), 6 (P 0.01), and
8 (P  0.05). Furthermore, Kaplan-Meier survival curve analy-
sis demonstrated that subconjunctival treatment improved sur-
vival rates to greater than 30% (P  0.008), whereas 0%
survival was observed among the untreated controls (Fig. 6).
Topical bevacizumab treatment also demonstrated 0% survival
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FIGURE 4. Analysis of topical versus subconjunctival bevacizumab on
the corneal NA, VC, and IA. High-risk graft beds in BALB/c mice were
transplanted with C57BL/6 cornea, and mice were left untreated (n 
10) or were treated topically (n  10) or subconjunctivally (n  10)
with bevacizumab. (A) Total area of blood vessels in each cornea was
calculated and normalized to the baseline to yield the mean NA at the
indicated time points to 8 weeks after transplantation. Although topical
bevacizumab treatment mildly reduced NA in high-risk corneal trans-
plantation, subconjunctival treatment resulted in a significant and
markedly reduced NA at weeks 4, 6, and 8. (B) Normalized mean values
for estimated blood vessel caliber at the indicated times to 8 weeks
after transplantation. Although the subconjunctival treatment group
significantly reduced VC at week 8 (P  0.03), topical bevacizumab
appeared to have a marginal statistical difference from the control
group (P  0.05). (C) The total area of each given cornea invaded by
blood vessels was calculated and normalized to yield the mean IA at the
indicated times to 8 weeks after transplantation. Subconjunctival bev-
acizumab treatment appeared to be the only effective method to
reduce IA. Student’s t-test was performed to evaluate statistical signif-
icance (*P  0.05; **P  0.01).
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FIGURE 5. Subconjunctival delivery of bevacizumab diminishes opac-
ity of corneal allografts in the high-risk setting. High-risk graft beds in
BALB/c mice were transplanted with C57BL/6 cornea, and mice were
left untreated (n  10) or were treated topically (n  10) or subcon-
junctivally (n  10) with bevacizumab. Corneal allografts were exam-
ined regularly to 8 weeks after transplantation by slit lamp, and graft
opacity was scored using a standard grading scheme. Student’s t-test
was performed to evaluate statistical significance (*P  0.05; **P 
0.01).
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FIGURE 6. Subconjunctival bevacizumab promotes corneal allograft
survival in the high-risk setting. High-risk graft beds in BALB/c mice
were transplanted with C57BL/6 cornea, and mice were left untreated
(n  10) or were treated topically (n  10) or subconjunctivally (n 
10) with bevacizumab. Kaplan-Meier curves were plotted to evaluate
the effect of topical versus subconjunctival bevacizumab treatment on
graft survival. Log rank test was performed to evaluate statistical sig-
nificance (**P  0.008).
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(Fig. 6), though rejection was delayed relative to the untreated
controls (P  0.05).
DISCUSSION
Corneal NV has long been established as an important risk
factor for immune rejection after corneal transplantation, yet
an effective treatment has remained elusive. The data from our
experiments using a mouse model of high-risk keratoplasty
suggest that both topical and subconjunctival bevacizumab
treatment can diminish the severity of corneal NV. However,
only subconjunctival bevacizumab treatment results in a signif-
icant regression of all neovessel metrics, including NA, VC, and
IA. Moreover, only subconjunctival bevacizumab treatment
significantly promotes graft survival in the high-risk setting.
Although topical administration of bevacizumab results in a
mild to moderate decrease in the severity of corneal NV,
topical bevacizumab shows little impact on graft survival in the
experimental model of high- risk transplantation described
here. These findings strongly suggest that topical application of
bevacizumab may not be able to provide adequate anti-VEGF
activity to impact graft survival compared with the subconjunc-
tival route.
It is likely that the limited efficacy of topical bevacizumab
results, at least in part, from a lack of adequate penetration
through the corneal epithelium. Healthy corneal epithelium
contains several layers of cells connected by tight junctions,
thus acting as an effective barrier for large molecules.32 Full-
length immunoglobulins, including bevacizumab, with molec-
ular weights of 149 kDa likely have limited capacity to pene-
trate the intact cornea. Nonetheless, conditions such as
inflammation have a significant effect on the corneal epithe-
lium; indeed, it is known that patients with, for example,
ocular surface disease have an incompetent barrier function.33
Moreover, the clinical efficacy of topical bevacizumab in the
treatment of corneal NV has been shown by our group27 and
by other investigators,21,23–25,34 indirectly suggesting that top-
ical bevacizumab may penetrate the epithelial barrier in pa-
tients with corneal inflammatory NV. This is also supported by
our work in a mouse model of corneal NV that has clearly
demonstrated bevacizumab can penetrate the neovascularized
cornea after topical application (Sadrai Z, et al. IOVS 2008;49:
ARVO E-Abstract 1488). Taken together, however, it is appar-
ent that the level of corneal penetration by topical application
of bevacizumab is insufficient in markedly improving corneal
NV and significantly promoting allograft survival in high-risk
graft beds. In contrast, subconjunctival injection of bevaci-
zumab can bypass the ocular surface epithelial barrier and can
produce high corneal levels of drug that lead to a significant
suppression of corneal NV, hence promoting graft survival in
high-risk settings.
Although our results with subconjunctival bevacizumab
were highly significant, the inhibition of corneal NV was far
from complete for several possible reasons. First, it is possible
that the dosage and duration of treatment were insufficient to
effectively antagonize all VEGF activity. Because of concern
regarding the potential adverse effects of bevacizumab in treat-
ing corneal NV,24 we sought to limit our treatment of bevaci-
zumab to the first few weeks after transplantation. Similarly,
bevacizumab is a humanized monoclonal antibody, and thus its
potency in murine models could be significantly impaired.35,36
Second, preexisting “stable” or “mature” vessels in the recipi-
ent bed may not be as susceptible as developing vessels to
anti-VEGF treatment.37 Third, it is clear that other relevant
proangiogenic factors (including FGF, IL-1, TNF-, and IFN-)
are also upregulated during wound healing and inflamma-
tion.38–40 Fourth, even in relation to VEGFR2-mediated signal-
ing, it is notable that bevacizumab is a specific antibody for
VEGF-A only; other ligands to VEGFR2 (e.g., VEGF-C) are not
directly suppressed by bevacizumab.
Corneal NV is almost invariably associated with higher graft
rejection rates, and blood vessel levels at the time of transplan-
tation are significantly correlated with graft survival.41,42
Khoadadoust43 reported that endothelial rejection occurred in
3.5% of avascular cases, 13.3% of mildly vascular cases, 28% of
moderately vascular cases, and 65% of heavily vascular cases. In
the present study, significant and marked regression of all three
metrics collectively, which occurred only with subconjunctival
treatment, has demonstrated a clear association with improved
graft survival rate. Although topical treatment with bevaci-
zumab resulted in a limited decrease in the severity of corneal
NV, it could not increase graft survival. These findings could
further underscore the significant relationship between size
and extent of corneal blood vessels and chance of graft rejec-
tion. Corneal blood vessels allow an influx of immune effector
cells to the corneal matrix. Therefore, the extent and size of
corneal NV, including neovessel area, the caliber of neovessels,
and the corneal area invaded by neovessels, particularly the
portion of NV that crosses into the graft, may well be crucial
for the efferent arm of immunity (facilitating delivery of
alloreactive T cells), which is detrimental to corneal graft
survival.14
To conclude, subconjunctival administration of bevaci-
zumab is more effective than topical administration in treating
corneal NV and promoting corneal graft survival in a mouse
model of high-risk transplantation. Subconjunctival bevaci-
zumab could potentially offer an adjunctive measure to con-
ventional therapies in preventing graft rejection in vascularized
high-risk corneal transplantation. More research, however, is
needed to define the optimal dosage and frequency of admin-
istration to achieve the best clinical outcomes. Moreover, given
our previous clinical results with topical bevacizumab in de-
creasing corneal NV27 and our data in this study (using a
humanized antibody in a mouse model of corneal NV), topical
bevacizumab, which clearly is efficacious in suppressing cor-
neal NV, may also (particularly at higher dosing regimens than
the one used in this study) be efficacious in preventing graft
rejection in high-risk corneal transplantation, warranting fur-
ther study.
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